JP2015532296A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015532296A5 JP2015532296A5 JP2015535036A JP2015535036A JP2015532296A5 JP 2015532296 A5 JP2015532296 A5 JP 2015532296A5 JP 2015535036 A JP2015535036 A JP 2015535036A JP 2015535036 A JP2015535036 A JP 2015535036A JP 2015532296 A5 JP2015532296 A5 JP 2015532296A5
- Authority
- JP
- Japan
- Prior art keywords
- antimetabolite
- pharmaceutically acceptable
- combination
- masitinib
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12306214 | 2012-10-04 | ||
| EP12306214.3 | 2012-10-04 | ||
| PCT/EP2013/070741 WO2014053650A1 (en) | 2012-10-04 | 2013-10-04 | Use of masitinib for treatment of cancer in patient subpopulations identified using predictor factors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015532296A JP2015532296A (ja) | 2015-11-09 |
| JP2015532296A5 true JP2015532296A5 (enExample) | 2016-11-10 |
| JP6234466B2 JP6234466B2 (ja) | 2017-11-22 |
Family
ID=47073382
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015535036A Active JP6234466B2 (ja) | 2012-10-04 | 2013-10-04 | 予測因子を用いて同定された患者サブ集団における癌の処置のためのマシチニブの使用 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US10238649B2 (enExample) |
| EP (1) | EP2903616B8 (enExample) |
| JP (1) | JP6234466B2 (enExample) |
| KR (1) | KR102149483B1 (enExample) |
| CN (1) | CN104968347A (enExample) |
| AR (1) | AR092899A1 (enExample) |
| AU (1) | AU2013326463B2 (enExample) |
| BR (1) | BR112015007144A2 (enExample) |
| CA (1) | CA2886979C (enExample) |
| DK (1) | DK2903616T3 (enExample) |
| EA (1) | EA037368B1 (enExample) |
| ES (1) | ES2656640T3 (enExample) |
| IL (1) | IL238107B (enExample) |
| MX (1) | MX369999B (enExample) |
| NZ (1) | NZ706420A (enExample) |
| SG (1) | SG11201502626PA (enExample) |
| SI (1) | SI2903616T1 (enExample) |
| TW (1) | TWI609686B (enExample) |
| WO (1) | WO2014053650A1 (enExample) |
| ZA (1) | ZA201503054B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015049377A1 (en) * | 2013-10-04 | 2015-04-09 | Ab Science | Method for determining the prognosis of pancreatic cancer |
| MX2016014574A (es) * | 2014-05-08 | 2017-02-23 | Oncoethix Gmbh | El uso de compuestos de tienotriazolodiazepina para el tratamiento de cancer de mama triple-negativo. |
| WO2016062265A1 (zh) * | 2014-10-24 | 2016-04-28 | 朗齐生物医学股份有限公司 | 莫诺苯宗药物在用于制备治疗癌症的医药组合物中的用途 |
| WO2016162229A1 (en) | 2015-04-10 | 2016-10-13 | Capsugel Belgium N.V. | Abiraterone acetate lipid formulations |
| JOP20170053B1 (ar) | 2016-03-02 | 2021-08-17 | Eisai Randd Man Co Ltd | مترافقات جسم مضاد وعقار أساسها إيريبولين وطرق استخدامها |
| SG11201808106YA (en) * | 2016-03-25 | 2018-10-30 | Ab Science | Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation |
| CN107267454B (zh) * | 2016-04-07 | 2025-05-23 | 内蒙古原生元生物科技有限公司 | 一种脐血nk细胞的体外扩增方法及其试剂盒与应用 |
| MX393780B (es) | 2017-01-17 | 2025-03-24 | Heparegenix Gmbh | Inhibidores de proteina cinasa para promover la regeneracion hepatica o reducir o prevenir la muerte de hepatocitos |
| EP3576733A4 (en) * | 2017-02-01 | 2020-11-25 | Beyondspring Pharmaceuticals, Inc. | NEUTROPENIA REDUCTION METHOD |
| EA202091763A1 (ru) * | 2018-01-31 | 2020-12-14 | ДЕСИФЕРА ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | Комбинированная терапия для лечения мастоцитоза |
| US20210398672A1 (en) * | 2018-10-29 | 2021-12-23 | Northwestern University | Big Data-Driven Personalized Management of Chronic Pain |
| WO2020115108A1 (en) * | 2018-12-06 | 2020-06-11 | Sørlandet Sykehus Hf | Egfr inhibitors and their use in the treatment of neuroathic pain |
| WO2020115261A1 (en) * | 2018-12-07 | 2020-06-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treating melanoma |
| EP3938363A1 (en) | 2019-03-11 | 2022-01-19 | Teva Pharmaceuticals International GmbH | Solid state forms of ripretinib |
| JP7818502B2 (ja) | 2019-08-12 | 2026-02-20 | デシフェラ・ファーマシューティカルズ，エルエルシー | 胃腸間質腫瘍を治療するためのリプレチニブ |
| AU2020417282B2 (en) | 2019-12-30 | 2023-08-31 | Deciphera Pharmaceuticals, Llc | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea |
| CN111759857A (zh) * | 2020-06-30 | 2020-10-13 | 宁波市微循环与莨菪类药研究所 | Gabrd甲基化靶点在制备抗海洛因复吸药物中的应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8450302B2 (en) * | 2002-08-02 | 2013-05-28 | Ab Science | 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors |
| MXPA05001277A (es) | 2002-08-02 | 2005-10-06 | Ab Science | 2-(3-aminoaril)amino-4-aril-tiazoles y su uso como inhibidores del c-kit. |
| US20090298061A1 (en) | 2005-07-29 | 2009-12-03 | Siemens Healthcare Diagnostics Inc. | Diagnostic Methods for the Prediction of Therapeutic Success, Recurrence Free and Overall Survival in Cancer Therapy |
| US20100143935A1 (en) * | 2006-12-01 | 2010-06-10 | Apocell, Inc. | c-KIT Phosphorylation in Cancer |
| JP2010515708A (ja) | 2007-01-12 | 2010-05-13 | アブ サイエンス | 代謝拮抗薬およびチロシンキナーゼ阻害剤を用いた固形癌の併用治療 |
| AU2008214679A1 (en) | 2007-02-13 | 2008-08-21 | Ab Science | Process for the synthesis of 2-aminothiazole compounds as kinase inhibitors |
| US20120264639A1 (en) | 2009-11-04 | 2012-10-18 | Jen Jen Yeh | Methods and compositions for predicting survival in subjects with cancer |
| WO2011092338A1 (en) * | 2010-02-01 | 2011-08-04 | Ab Science | Combined treatment of pancreatic cancer with gemcitabine and masitinib |
| WO2012170640A1 (en) * | 2011-06-07 | 2012-12-13 | The Trustees Of Columbia University In The City Of New York | Methods and compositions for trail-drug combination therapy |
-
2013
- 2013-10-04 MX MX2015004264A patent/MX369999B/es active IP Right Grant
- 2013-10-04 WO PCT/EP2013/070741 patent/WO2014053650A1/en not_active Ceased
- 2013-10-04 EP EP13773731.8A patent/EP2903616B8/en active Active
- 2013-10-04 SG SG11201502626PA patent/SG11201502626PA/en unknown
- 2013-10-04 EA EA201500373A patent/EA037368B1/ru unknown
- 2013-10-04 KR KR1020157011764A patent/KR102149483B1/ko active Active
- 2013-10-04 AR ARP130103596A patent/AR092899A1/es unknown
- 2013-10-04 NZ NZ706420A patent/NZ706420A/en not_active IP Right Cessation
- 2013-10-04 BR BR112015007144A patent/BR112015007144A2/pt not_active Application Discontinuation
- 2013-10-04 SI SI201330891T patent/SI2903616T1/en unknown
- 2013-10-04 JP JP2015535036A patent/JP6234466B2/ja active Active
- 2013-10-04 TW TW102136110A patent/TWI609686B/zh not_active IP Right Cessation
- 2013-10-04 CN CN201380063241.4A patent/CN104968347A/zh active Pending
- 2013-10-04 DK DK13773731.8T patent/DK2903616T3/da active
- 2013-10-04 CA CA2886979A patent/CA2886979C/en active Active
- 2013-10-04 US US14/433,198 patent/US10238649B2/en active Active
- 2013-10-04 ES ES13773731.8T patent/ES2656640T3/es active Active
- 2013-10-04 AU AU2013326463A patent/AU2013326463B2/en not_active Ceased
-
2015
- 2015-04-01 IL IL238107A patent/IL238107B/en active IP Right Grant
- 2015-04-08 ZA ZA2015/03054A patent/ZA201503054B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015532296A5 (enExample) | ||
| MX2024010140A (es) | Nuevos metodos. | |
| PH12015502691A1 (en) | Use of high dose pridopidine for treating huntington's disease | |
| CY1119490T1 (el) | Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων | |
| JP2016528301A5 (enExample) | ||
| JP2017506624A5 (enExample) | ||
| JP2016147915A5 (enExample) | ||
| JP2015524444A5 (enExample) | ||
| EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
| PH12014502447A1 (en) | Use of high dose laquinimod for treating multiple sclerosis | |
| BR112015025464A2 (pt) | coagonistas do receptor de glp-1/glucagon estáveis, prolongados para uso médico | |
| MX2015016344A (es) | Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades. | |
| FI3504187T3 (fi) | Pridopidiinin käyttö toiminnallisen heikkenemisen hoitoa varten | |
| BR112015018168A2 (pt) | inibidores de rock suaves | |
| JP2015523407A5 (enExample) | ||
| TR201909277T4 (tr) | Rasajilinin genişletilmiş salınım formülasyonları ve kullanım alanları. | |
| NZ700924A (en) | Dosage regimen for a pi-3 kinase inhibitor | |
| RU2017141536A (ru) | Замещенные производные индол-5-ола и их терапевтические применения | |
| WO2014130691A3 (en) | Pharmaceutical formulations of nitrite and uses thereof | |
| MX341660B (es) | Agonista del receptor de ghrelina para el tratamiento de caquexia. | |
| MX2016008027A (es) | Uso de laquinimod para retrasar la evolucion de la enfermedad de huntington. | |
| HRP20251123T1 (hr) | Ekopipam za liječenje touretteovog sindroma | |
| JP2016528283A5 (enExample) | ||
| MX2021007324A (es) | Terapia oral con acido 6,8-bis-benciltio-octanoico. | |
| JP2015515971A5 (enExample) |